cjc-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
They are assigned to one of four risk categories based on their virulence, the severity of the disease, the mode of transmission, and the availability of preventive measures or treatments. There are four biosafety levels that a laboratory can fall into, ranging from level 1 (which is suitable for working with agents not associated with disease) to level 4 (working with life-threatening agents). Different countries use different nomenclature to describe the levels and can have different requirements for what can be done at each level.
Psilocybin is dephosphorylated into its active form psilocin in the body and hence is a prodrug. Psilocybin is metabolized in the intestines, liver, kidneys, blood, and other tissues and bodily fluids. There is significant first-pass metabolism of psilocybin and psilocin with oral administration. No psilocybin has been detected in the blood in humans after oral administration, suggesting virtually complete dephosphorylation into psilocin with the first pass. It is also said to be converted 90% to 97% into psilocin. The competitive phosphatase inhibitor β-glycerolphosphate, which inhibits psilocybin dephosphorylation, greatly attenuates the behavioral effects of psilocybin in rodents. Psilocybin undergoes dephosphorylation into psilocin via the acidic environment of the stomach or the actions of alkaline phosphatase (ALP) and non-specific esterases in tissues and fluids. Psilocin is demethylated and oxidatively deaminated by monoamine oxidase (MAO), specifically monoamine oxidase A (MAO-A), into 4-hydroxyindole-3-acetaldehyde (4-HIAL or 4-HIA). 4-HIAL is then further oxidated into 4-hydroxyindole-3-acetic acid (4-HIAA) by aldehyde dehydrogenase (ALDH) or into 4-hydroxytryptophol (4-HTOL or 4-HTP) by alcohol dehydrogenase (ALD). Deamination of psilocin by MAO-A appears to be responsible for about 4% or 33% of its metabolism in different studies. In contrast to psilocin, its metabolites 4-HIAA and 4-HTP showed no affinity for or activation of multiple serotonin receptors and are considered inactive.
== Cell cycle regulation == The eukaryotic cell cycle is regulated through the synthesis, degradation, binding interactions, post-translational modifications of regulatory proteins. Of these regulatory proteins, two ubiquitin ligases are crucial for progression through cell cycle checkpoints. The anaphase-promoting complex (APC) controls the metaphase-anaphase transition, while the SCF complex controls G1/S and G2/M transitions. Specifically, SCF has been shown to regulate centriole splitting from late telophase to the G1/S transition. SCF activity is largely regulated by post-translational modifications. For instance, ubiquitin-mediated autocatalytic degradation of FBPs is a mechanism of decreasing SCF activity. Well-characterized cell cycle substrates of SCF complexes include:
Seaborg's discovery that the actinides were in fact f-block rather than d-block elements. The periodic table and law have become a central and indispensable part of modern chemistry. The periodic table continues to evolve with the progress of science. In nature, only elements up to atomic number 94 exist; elements beyond that are synthetic elements that can only be obtained artificially. By 2010, the first 118 elements were known, thereby completing the first seven rows of the table; however, chemical characterization is still needed for the heaviest elements to confirm that their properties match their positions. New discoveries will extend the table beyond these seven rows, though it is not yet known how many more elements are possible; moreover, theoretical calculations suggest that this unknown region will not follow the patterns of the known part of the table. Some scientific discussion also continues regarding whether some elements are correctly positioned in the table. Many alternative representations of the periodic law exist, and there is some discussion as to whether there is an optimal form of the periodic table.
Sources: en.wikipedia.org
The Dexcom G5 was the first Dexcom continuous glucose monitor to be compatible with a mobile application. The accompanying app, named "Dexcom G5," allowed users to view their blood glucose readings on a smartphone and, with an intermediary iPhone, on an Apple Watch. The app remained available until the discontinuation of the Dexcom G5, at which point it was removed from app stores. The Dexcom G6 continued this functionality with its own dedicated application, "Dexcom G6," which provided real-time glucose readings and data-sharing capabilities. Upon the release of the Dexcom G7, a new application, "Dexcom G7," was introduced to support the updated system. The Dexcom G7 app is also available as the first system that connects directly to a smart watch. The Stelo by Dexcom also has an app which is similar to that of the G7, but has slightly different options.
Filtering helps stabilise the flavour of beer, holding it at a point acceptable to the brewer, and preventing further development from the yeast, which under poor conditions can release negative components and flavours. Filtering also removes haze, producing a clear beer with a "polished shine and brilliance". Clear beer became commercially desirable with the increasing use of glass drinking vessels and the development of pale lagers. During lagering, suspended material settles out, allowing the beer to "drop bright" and develop a naturally clear appearance. There are several forms of filters; they may be in the form of sheets or "candles", or they may be a fine powder such as diatomaceous earth (also called kieselguhr), which is added to the beer to form a filtration bed which allows liquid to pass, but holds onto suspended particles such as yeast. Filters range from rough filters that remove much of the yeast and any solids (e.g., hops, grain particles) left in the beer, to filters tight enough to strain colour and body from the beer. Filtration ratings are divided into rough, fine, and sterile. Rough filtration leaves some cloudiness and some character in the beer, while Fine filtration removes almost all cloudiness and microorganisms. Polysaccharides, proteins, yeast, bacteria and the brewing process may affect filtration.
== Small molecule drug candidates == The key amino acids of the BSCI peptides required for activity have been identified, and the tripeptide AcNH-Trp-Val-Gln-OH was shown to itself be a BSCI in the low micromolar range. Based on this structure a number of peptide mimetics were designed, including a range of 3-acylaminoglutarimides, with low nanomolar BSCI potencies. The search for increased stability and potency led to the development of 3-acylaminolactams, with picomolar potencies in vitro and high anti-inflammatory activity in vivo. A small molecule member of this class of BSCIs called FX125L, under development by Funxional Therapeutics, has recently completed phase 2 clinical trials.
The slide shows at (1) an epithelial cell infected by Chlamydia pneumoniae; their inclusion bodies shown at (3); an uninfected cell shown at (2) and (4) showing the difference between an infected cell nucleus and an uninfected cell nucleus. Epithelium grown in culture can be identified by examining its morphological characteristics. Epithelial cells tend to cluster together, and have a "characteristic tight pavement-like appearance". But this is not always the case, such as when the cells are derived from a tumor. In these cases, it is often necessary to use certain biochemical markers to make a positive identification. The intermediate filament proteins in the cytokeratin group are almost exclusively found in epithelial cells, so they are often used for this purpose. Cancers originating from the epithelium are classified as carcinomas. In contrast, sarcomas develop in connective tissue. When epithelial cells or tissues are damaged from cystic fibrosis, sweat glands are also damaged, causing a frosty coating of the skin.
A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the arteries of the heart, causing infarction (tissue death) to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn. This is the dangerous type of acute coronary syndrome. Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat, feeling tired, and decreased level of consciousness. Women more often present without chest pain and instead have neck pain, arm pain or feel tired. Among those over 70-75 years old, about 5% have had an MI with little or no history of symptoms. An MI may cause heart failure, an irregular heartbeat, cardiogenic shock or cardiac arrest. Most MIs occur due to coronary artery disease. Risk factors include high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol intake. The complete blockage of a coronary artery caused by a rupture of an atherosclerotic plaque is usually the underlying mechanism of an MI. MIs are less commonly caused by coronary artery spasms, which may be due to cocaine, significant emotional stress (often known as Takotsubo syndrome or broken heart syndrome) and extreme cold, among others. Many tests are helpful with diagnosis, including electrocardiograms (ECGs), blood tests and coronary angiography.
Sources: en.wikipedia.org
== Management == Oxygen therapy may assist with daily living. In case of idiopathic pulmonary fibrosis, certain medications like nintedanib and pirfenidone can help slow the progression. Lastly, lung transplants may help.
== Nutritional profile == Sirloin steak is a nutrient-dense source of protein and contains essential micronutrients. A 100 g serving of cooked sirloin steak typically provides 200-313 kilocalories. It contains 28-30 g of protein, 0 g of carbohydrates and 9-21 g of fat, depending on the cooking method and trimming. The cut is generally leaner than heavily marbled steaks, such as ribeye, which results in a lower total fat content. A 100 g sirloin steak also contains 2–3 mg of iron and 3 mg of vitamin B12. These vitamins are important for oxygen transport and neurological function.
Some vape pens, generally not referred to as "e-cigarettes", contain cannabis derivatives instead of nicotine and tobacco derivatives. Some cannabis pens, known as "dab pens", contain cannabis extracted using butane as solvent ("butane hash oil"). Other vaporizers contain e-liquid made with pure THC, and they generally resemble conventional e-cigarettes. A 2020 study shows that one third of teenagers engaged in conventional, tobacco vaping also engage in THC vaping. KanaVape is an e-cigarette containing cannabidiol (CBD) and no THC. Several companies including Canada's Eagle Energy Vapor are selling caffeine-based e-cigarettes instead of containing nicotine. Some e-cigarettes marketed as being "nicotine-free" have been found to instead contain the nicotine analogue 6-methylnicotine, which is more potent and may be more addictive than nicotine itself. More broadly, vape pens and e-liquids have become increasingly widely used as a delivery mechanism for a wide variety of illicit and designer drugs. These can include stimulants such as methamphetamine and cocaine, opioids such as fentanyl analogs and nitazenes, a wide variety of synthetic cannabinoids as well as semi-synthetic cannabinoids derived from THC, sedatives including benzodiazepines like etizolam as well as etomidate and methaqualone, psychedelics such as NBOMe substituted phenethylamine derivatives, dissociatives such as ketamine, and assorted other compounds.
Tissue transaminase activities can be investigated by incubating a homogenate with various amino/keto acid pairs. Transamination is demonstrated if the corresponding new amino acid and keto acid are formed, as revealed by paper chromatography. Reversibility is demonstrated by using the complementary keto/amino acid pair as starting reactants. After chromatogram has been taken out of the solvent the chromatogram is then treated with ninhydrin to locate the spots.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.